BioFluidica
Chapel Hill, US · Founded 2013 · North Carolina corporation
Find your way into BioFluidica
277 people in our graph share verified history with the BioFluidica team — schools, employers, funds. One of them is your warm intro.
Tristan Huntunlockedknows Rolf Muller · together at Digitalis Commons (overlapped)
×4knows the team · via SALK Institute
×5knows the team · via Université Paris Cité
×2knows the team · via Oregon State University
BioFluidica is a privately held biotechnology company that develops an automated liquid biopsy platform, LiquidScan, for isolating and analyzing rare cells, extracellular vesicles (exosomes), and cfDNA from blood and plasma samples. Its instruments, reagents, and software—offered for research use—support applications in oncology and prenatal testing, including circulating tumor cell and fetal trophoblast isolation.
Founders & leadership
BioFluidica was founded in 2013 by Steven Soper.
SS
Steven SoperFounder
RM
Rolf MullerinChief Executive Officer2015–2024Rolf Müller is Chief Executive Officer of BioFluidica, a biotechnology company developing automated liquid biopsy platforms. With 16 years of experience in the biotechnology sector, he has led cross-functional research and commercial teams through product development and market launch, and has secured funding from venture investors and government agencies including the NIH, DARPA, and DOD.
Board
ST
Sam TetlowBoard director
MS
Michael StocumBoard director
Reported raises · per SEC filings
Form D private placements$18.7M disclosed across 5 rounds · 2016–2021
▶$3.5MraisedDec 2021 · 12 investors · Other TechnologyRule 506(b)
▶$3.5MraisedDec 2021 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- ROLF MULLERExecutive Officer, Director
- JUDY MULLER-COHNExecutive Officer
- STEVEN SOPERExecutive Officer, Director
- MICHAEL STOCUMDirector
- PHILIP BUCHANANDirector
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Nov 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$6MraisedMar 2021 · 22 investors · Other TechnologyRule 506(b)
▶$6MraisedMar 2021 · 22 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Sam C. TetlowExecutive Officer, Director
- Rolf MullerExecutive Officer, Director
- Michael StocumDirector
- Steven SoperExecutive Officer, Director
- Judy Muller-CohnExecutive Officer
- Philip D. BuchananDirector
- Offering amount
- $8.2M
- Amount sold
- $6M
- First sale
- Nov 2019
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$3MraisedNov 2019 · 18 investors · Other TechnologyRule 506(b)
▶$3MraisedNov 2019 · 18 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Rolf MullerExecutive Officer, Director
- Sam TetlowExecutive Officer, Director
- Michael StocumDirector
- Steven SoperDirector
- Philip D. BuchananDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Aug 2018
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$4.1MraisedJul 2017 · 9 investors · Other TechnologyRule 506(b)
▶$4.1MraisedJul 2017 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Philip D. BuchananDirector
- Michael StocumDirector
- Steven SoperDirector
- Sam TetlowExecutive Officer, Director
- Rolf MullerExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $4.1M
- First sale
- Jul 2017
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
▶$2MraisedJun 2016 · 10 investors · Other TechnologyRule 506(b)
▶$2MraisedJun 2016 · 10 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Rolf MullerExecutive Officer, Director
- Michael StocumDirector
- Steven SoperDirector
- Sam TetlowDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Apr 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with BioFluidica for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $291.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $348.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $286.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $239.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $399.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $999.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does BioFluidica do?
- BioFluidica is a privately held biotechnology company that develops an automated liquid biopsy platform, LiquidScan, for isolating and analyzing rare cells, extracellular vesicles (exosomes), and cfDNA from blood and plasma samples. Its instruments, reagents, and software—offered for research use—support applications in oncology and prenatal testing, including circulating tumor cell and fetal trophoblast isolation.
- Who founded BioFluidica?
- BioFluidica was founded by Steven Soper in 2013.
- How much funding has BioFluidica raised?
- BioFluidica has disclosed $18.7M raised across 5 rounds.
- Where is BioFluidica headquartered?
- BioFluidica is headquartered in Chapel Hill, US.